ArticleMedicine2026
Machine learning diagnostic framework for liver fibrosis in chronic hepatitis B based on routine laboratory tests.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and internal validation of a CatBoost-SHAP-guided nomogram for significant liver fibrosis in children with chronic hepatitis B.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of liver fibrosis in chronic hepatitis B (CHB) patients is crucial for improving their prognosis. This study aims to develop a machine learning (ML)-based diagnostic model for evaluating the degree of liver fibrosis in patients with CHB. The present study comprised 268 patients with CHB who underwent liver biopsy from January 2022 to May 2023. Liver fibrosis was staged according to the Scheuer scoring system. The dataset is divided into a training set and a validation set in a ratio of 7.5:2.5. The feature selection process was executed through the utilization of least absolute shrinkage and selection operator regression, and 8 ML algorithms (including random forest [RF], extreme gradient enhancement, support vector machine, etc) were employed for the prediction of the performance of the significant liver fibrosis assessment model. The RF model performs best among ML models, with an area under the curve value of 0.810 for the training set and 0.793 for the validation set. Decision curve analysis indicates that the RF model exhibits the highest net benefit under most threshold probabilities. When the probability threshold is 30%, the sensitivity and net benefit are the highest, significantly outperforming other traditional scores. RF ML models can effectively assess liver fibrosis in patients with CHB. Compared with traditional indicators, they can become a safe, effective and more personalized screening method, enabling early and dynamic risk decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.